Drug
Efgartigimod Ph20 AS A Presentation
Efgartigimod Ph20 AS A Presentation: highest development phase Phase 1, developed by Argenx. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Argenx
Trials
| Drug | Phase | Indication |
|---|---|---|
| efgartigimod PH20 SC as a prefilled syringe presentation NCT05817435 | Phase 1 | Bioequivalence |
Latest
No recent events.
Follow Efgartigimod Ph20 AS A Presentation on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.